Glutamic acid decarboxylase 65-derived peptide-HLA class II complex (GAD65-HLA-II)

The Glutamic acid decarboxylase 65-derived peptide-HLA class II complex is a critical molecular assembly involved in the autoimmune recognition of pancreatic beta cells. GAD65 (encoded by the GAD2 gene) is a key enzyme in GABA biosynthesis and a primary autoantigen in Type 1 Diabetes (T1D) (UniProt: Q05329). In genetically susceptible individuals, specific GAD65-derived peptides, such as GAD65(555–567), are loaded into the binding groove of HLA class II molecules like HLA-DRB1*04:01 for presentation to CD4+ T cells (PubMed: 25231403). This interaction is a prerequisite for the activation of the autoreactive T-cell repertoire that drives pancreatic inflammation and beta-cell destruction (NIH: PMC4939732). Therapeutic strategies targeting this complex, including antigen-specific immunotherapies like GAD-alum (Diamyd), seek to reprogram the immune system toward a state of tolerance (PubMed: 33027073). By focusing on the peptide-MHC interface, these treatments aim to selectively inhibit the autoimmune response while maintaining overall immune competence. Understanding the structural interaction between the GAD65 peptide and the HLA groove is essential for developing precision therapies that spare the rest of the immune system.

Other names

GAD65 peptide-MHC II complexGAD65-HLA-DR4 complexGAD65-HLA-DQ8 complexGAD65 autoantigen-HLA complex

Induction of antigen-specific immune tolerance by modulating the T-cell response to GAD65 peptides presented by HLA class II molecules, often shifting the immune profile from a pro-inflammatory Th1 response to a regulatory or Th2-mediated response.